Silexion partners with Catalent for siRNA formulation and manufacturing of SIL204

Silexion Therapeutics Corp

Collaboration with Catalent for SIL204 formulation development and clinical manufacturing at Limoges, France facility.
SIL204 targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, G13D) in pancreatic, colorectal, and lung cancers.
Company plans to initiate human clinical trials for SIL204 in first half of 2026.
Preclinical data showed significant reduction in primary tumor growth and metastatic spread in pancreatic cancer models.
Regulatory submissions to Israel Ministry of Health expected H2 2025 and to EU in H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.